Cholangiocarcinoma.

Crit Rev Oncol Hematol

Medical Oncology Unit, Giovanni XXIII Hospital, Bergamo, Italy.

Published: August 2017

Biliary tract cancer accounts for <1% of all cancers and affects chiefly an elderly population, with predominance in men. We distinguish cholangiocarcinoma (intrahepatic, hilar and distal) and gallbladder cancer, with different pathogenesis and prognosis. The treatment is based on surgery (whenever possible), radiotherapy in selected cases, and chemotherapy. The standard cytotoxic treatment for advanced/metastatic disease is represented by the combination of gemcitabine and cisplatin, whereas fluoropyrimidines are generally administered in second line setting. At the present time, no biologic drug demonstrated a clear efficacy in this cancer, although the molecular characterisation could provide a promising basis for experimental treatments. A good supportive care and an early palliative care are warranted in most patients and should be delivered as a part of a global approach.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2016.11.012DOI Listing

Publication Analysis

Top Keywords

cholangiocarcinoma biliary
4
biliary tract
4
tract cancer
4
cancer accounts
4
accounts for 
4
cholangiocarcinoma
1
tract
1
cancer
1
accounts
1
for 
1

Similar Publications

Recent 5‑year trends in biliary tract cancer survival rates: An analytical big data survey.

Med Int (Lond)

January 2025

Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul 02841, Republic of Korea.

Biliary tract cancer (BTC), also known as cholangiocarcinoma, is a relatively rare type of cancer with a poor prognosis. Despite the combination of chemotherapy and advances in targeted therapy, which have potentially improved the prognosis of patients with BTC, research on outcomes remains inadequate. The present study thus analyzed the survival trends of patients with BTC.

View Article and Find Full Text PDF

Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape.

Hepat Oncol

December 2024

Gastrointestinal Malignancies Section, Thoracic & GI Malignancies Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD 20892, USA.

Precision medicine has emerged as a cornerstone in cancer treatment revolutionizing our approach across malignancies. Molecular profiling of biliary tract cancers (BTCs) has changed the treatment landscape positively by prolonging survival in an aggressively fatal malignancy in its advanced stages. The acquisition of tissue tumor DNA for genomic analysis in BTC is often anatomically challenging, limited by quantity and quality.

View Article and Find Full Text PDF

Diagnostic cholangioscopy for surgical planning of extrahepatic cholangiocarcinoma.

Sci Rep

January 2025

Digestive Disease Center, CHA Bundang Medical Center, CHA University School of Medicine, 59 Yatap-ro, Seongnam-si, 13496, Gyeonggi-do, Republic of Korea.

The recent clinical outcomes of multi-regimen chemotherapy included prolonged survival and a high rate of conversion to surgery in Asian patients with advanced biliary tract cancer. The ability of single-operator cholangioscopy (SOC) to detect and stage extrahepatic cholangiocarcinoma (CCC) in intraductal lesions is becoming more important in determining the extent of surgery. The aim of this study was to evaluate the role of SOC in surgical planning for extrahepatic CCC.

View Article and Find Full Text PDF

Identifying predictive markers for survival in malignant biliary obstruction following percutaneous transhepatic biliary drainage.

Clin Radiol

December 2024

University Hospital Southampton, Southampton General Hospital, Tremona Road, Southampton, Hampshire, SO16 6YD, UK. Electronic address:

Aim: Malignant biliary obstructive disease is commonly managed with percutaneous transhepatic biliary drainage (PTBD). Traditionally, outcomes are evaluated collectively despite substantial variability in the underlying aetiology and extent of disease. The purpose of this study was to investigate whether variability in survival could be explained by different underlying patient and disease factors.

View Article and Find Full Text PDF

Background: Hepatic eosinophilic pseudotumor (HEPT) is a rare condition that mimics malignant hepatic tumors, posing significant diagnostic challenges. This case report highlights the importance of considering parasitic infections like () in the differential diagnosis of hepatic masses, especially in endemic regions, to prevent unnecessary interventions.

Case Summary: A 40-year-old female presented with a 1-month history of epigastric pain and significant weight loss.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!